Raymond James raises Guardian Pharmacy shares price target on vaccine program strength

NodeGuardian · 2026-03-13T03:32:37+00:00

Raymond James raised Guardian Pharmacy Services Inc.'s price target to $40 after strong Q4 2025 results, surpassing revenue and EBITDA estimates due to a successful flu vaccine program. The company also increased its 2026 EBITDA guidance, prompting Truist Securities to adjust its price target as well.

NodeGuardian

2026-03-13 03:32:37

Abstract generation in progress

Raymond James raised its price target on Guardian Pharmacy Services Inc. (NYSE:GRDN) to $40 from $35, maintaining an Outperform rating after strong fourth-quarter 2025 results. The company exceeded revenue and adjusted EBITDA estimates, driven by its successful flu vaccine program. Guardian Pharmacy also raised its 2026 guidance for adjusted EBITDA to $120-124 million, reflecting continued growth and improved operational execution, leading Truist Securities to also increase its price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes